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Abstract
Background: HCV is circulating as a heterogeneous group of quasispecies. It has been addressed
that siRNA can inhibit HCV replication in-vitro using HCV clone and/or replicon which have only
one genotype. The current study was conducted to assess whether siRNA can inhibit different
HCV genotypes with many quasispecies and to assess whether consensus siRNA have the same
effect as regular siRNA.
Methods: We generated two chemically synthesized consensus siRNAs (Z3 and Z5) which cover
most known HCV genotype sequences and quasispecies using Ambium system. Highly positive
HCV patient's serum with nine quasispecies was transfected in-vitro to Huh-7 cell line which
supports HCV genotype-4 replication. siRNA (Z3&Z5) were transfected according to Qiagen
Porta-lipid technique and subsequently cultured for eight days. HCV replication was monitored by
RT-PCR for detection of plus and minus strands. Real-time PCR was used for quantification of
HCV, whereas detection of the viral core protein was performed by western blot.
Results: HCV RNA levels decreased 18-fold (P = 0.001) and 25-fold (P = 0.0005) in cells
transfected with Z3 and Z5, respectively, on Day 2 post transfection and continued for Day 3 by Z3
a n dD a y7b yZ 5 .R e d u c t i o no fc o r ep r o t e i ne x p r e s s i o nw a sr e p o r t e da tD a y2p o s tZ 3s i R N A
transfection and at Day 1 post Z5 siRNA, which was persistent for Day 4 for the former and for
Day 6 for the latter.
Conclusion: Consensus siRNA could be used as a new molecular target therapy to effectively
inhibit HCV replication in the presence of more than one HCV quasispecies.
Background
Hepatitis C virus (HCV), a member of the Flaviviridae
family of viruses, is a major cause of chronic hepatitis
and hepatocellular carcinoma [1, 2]. Viral clearance
during acute HCV infection is usually associated with a
multispecific CD4
+ and CD8
+ T cell response, which is
weak or undetectable in subjects who do not control the
infection [3-5]. Importantly, most chronically infected
patients, especially those with genotype 4, fail to resolve
HCV infection after combination therapy with pegylated
IFN and ribavirin [6-8]. The HCV genome is a positive-
stranded 9.6-kb RNA molecule consisting of a single
ORF, which is flanked by 5 and 3 UTR. The HCV 5-UTR
contains a highly structured internal ribosome entry site
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Open Access[8-13]. The HCV ORF encodes a single polyprotein that
is 3,008–3,037 aa in length and is post- translationally
modified to produce at least ten different proteins: core,
envelope proteins (E1 and E2), p7, and nonstructural
proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) [2,
13, 14]. Despite considerable advances in understanding
the function of these proteins, the basic mechanism(s) of
HCV replication remains unclear. The recent develop-
ment of H CV culture and expression of HCV proteins in
stably transfected human cells has facilitated the analysis
of the role of cellular pathways required for HCV
replication and the efficacy of antiviral drugs [15, 16].
RNA interference (RNAi), originally discovered in plants,
Caenorhabditis elegans,a n dDrosophila,i sa l s oi n d u c e db y
dsRNA [17, 18]. In this process, dsRNA is cleaved into
21–23 nucleotides (known as short interfering RNA or
siRNA) by an RNase III-like enzyme known as Dicer
[19-21]. These siRNA molecules associate with a multi-
protein complex known as the RNA-induced silencing
complex and target homologous mRNA for degradation
[19-21]. RNAi, which can function independently of
IFN-induced pathways, is also effective in mammalian
c e l l s[ 2 0 ,2 2 ,2 3 ] .T h i ss u g g e s t st h a tp l a n t sa n da n i m a l s
share a conserved antiviral mechanism leading to
specific destruction of nonself dsRNA [24, 25]. RNAi
interferes with the replication of a number of animal
viruses including HIV-1, flock house virus (FHV), Rous
sarcoma virus, dengue virus, and poliovirus [26, 27].
As an RNA virus, HCV is a prime candidate for RNAi.
Indeed, it has been demonstrated recently that HCV-
specific siRNA can inhibit levels of a fusion NS5B-
luciferase reporter transcript when the siRNA and the
target were cotransfected hydrodynamically into mice
[8]. Also, Kapadia et al., [28] demonstrated that by using
HCV-specific siRNA, HCV RNA replication and protein
expression are efficiently inhibited in Huh-7 cells that
stably replicate the HCV replicon (genotype-1) and that
this effect is independent of IFN.
In the current study, we compared the effect of consensus
siRNA (specific for both the 5-UTR and Core) and
regular siRNA in inhibiting ongoing HCV genotype-4
replication using a recently developed HCV-4 tissue
culture system in Huh-7 cells.
Materials and methods
Design and Synthesis of siRNA
The current study included 60 patients positive for HCV
RNA by RT-PCR. Their HCV RNA 5-UTR was previously
sequenced in our lab by TRUGENE method [29, 30].
Their gene accession numbers were: AY661552,
AY673080–AY673111, AY624961–AY624986,
AY902780–AY902787. BIOEDIT V 7.0 program [31]
was used for sequence alignment editing, visualization,
and conservation, and positional entropy plots of all 155
sequences generated (representing all quasispecies from
those patients) and were used to generate the consensus
sequence (see additional file 1) as shown in Figures 1, 2.
This consensus sequence was used as a base for
generation of different siRNA using Ambion web-based
criteria. Five HCV-specific siRNA were detected based on
this consensus of the HCV 5-UTR. However, only two
siRNA were selected which showed 100% alignment
with HCV sequences in the gene data base and were able
to align in both core and 5-UTR. HCV-5UTR-Z5 59 {3'-
AACCCGCTCAATGCCCG/CGA-5') 79, sense strand
siRNA (3'-CCCGCUCAAUGCCCG/CGATT-5'), antisense
strand siRNA: (3'-UCG/CGGGCAUUGAGCGGGTT-5'}
and HCV-5UTR-Z3 41{3'-AAATTTGGGCGTG-
CCCCCGCA-5') 57, Sense strand siRNA: (3'-
AUUUGGGCGUGCCCCCGCATT-5'), antisense strand
siRNA: UGCGGGGGCACGCCCAAAUTT-5'}. This area
has no cross alignment with any other sequences on the
gene data base and within IRES of the HCV-5-UTR.
These siRNAs were chemically synthesized, HPLC pur-
ified and sterilized with ultra-filtration to remove any
interfering substances that might be toxic to culture
systems.
Huh-7 cell culture
Human hepatocellular carcinoma cell line Huh-7 was
used to establish the in vitro HCV replication. Huh-7
culturing and infection were carried out according to
previous protocols [32]. Briefly, Huh-7 cells were
maintained in 75 cm culture flasks (Greiner bio-one
GmbH, Germany) containing Dulbecco's Modified
Eagle's Medium (DMEM) supplemented with 4.5 g/L
glucose and 10 g/L L-glutamine (Bio Whittaker, a
Combrex Company, Belgium), 100 ml/L fetal calf
serum (FCS), 10 g/L penicillin/streptomycin and 1 g/L
fungizone 250 mg/L (Gibco-BRL life Technologies,
Grand Island, NY (USA). The complete culture medium
(CCM) was renewed every 3 days, and cells were
passaged every 6–10 days. The exact cells count was
recorded in 50 μl aliquots after mixing with equal
volume of trypan blue (5 g/L; Biochrom KG, Berlin,
Germany). A total of 3 × 10
6 cells were suspended in 10
ml complete medium and incubated at 37°C in 5% CO2.
Viral inoculation and sample collection
Viral inoculation and cell culture were done as pre-
viously described by el-Awadye ta l .[ 3 3 ] .B r i e f l y ,c e l l s
were grown for 48 h to semi-confluence in CCM, washed
twice with FCS-free medium, then inoculated with 500
μl serum obtained from HCV infected patients (RT-PCR
and antibody positive) (500 μl patient sera and 500 μl
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6 cells). The HCV genotype in the
used sera was previously characterized as genotype-4
with 9 quasispecies based on the method described
earlier [34]. The viral load in the used serum was
quantified by real time PCR. The average copy number
was 580 × 10
6copies/ml. After 180 min, Ham F12
medium (Bio Whittaker, a Combrex Company, Belgium)
containing FCS was added to make the overall serum
contents 100 ml/L in a final volume of 10 ml including
the volume of human serum used for infection as
mentioned above. Cells were maintained overnight at
37°C in 5% CO2. The next day, adherent cells were
washed with CCM and incubation was continued in
CCM with 100 ml/L FCS. Throughout the culture
duration, the viral RNA in Huh-7 cells was assessed
qualitatively by sodium dodecylsulphate polyacrylamide
gel electrophoresis (SDS-PAGE), for western blotting of
viral core antigens. RT-PCR amplification of sense and
anitsense strands were tested quantitatively by real time
PCR as discussed below.
siRNA Transfection Protocol Optimization
Since cells vary greatly with respect to their capacity to be
transfected, the transfection protocol for each cell line
should be determined empirically. Therefore, MAPK1
control Kit (Qiagen GmbH, D-40724 Hiden), GAPDH
siRNA and the GAPDH negative control siRNA
(Ambion) were used to optimize: 1) optimal cell plating
density, 2) optimal type of transfection agent either
siPORT amine (Silencer siRNA Transfection Kit Austin
TX, USA Cat#1630) or siPORT Lipid (Silencer siRNA
Transfection Kit Austin TX, USA Cat# 4505), 3) optimal
amount of siPORT transfection agent and whether to
transfect in serum-free or serum-containing medium,
and 4) optimal amount of siRNA. Accordingly, a highly
purified siRNA was obtained from Ambion and trans-
fected using siPORT Lipid Kit according to the manufac-
turer's instructions. Briefly, 0.5–2×1 0
5 Huh-7 infected
with HCV were plated in 12-well plates and after 3 days
100 nM of siRNA were transfected using siPORT
ATGGTGTTGTA/GCAGCCTCCAGGACCCCCCTCC
CGGGAGAGCCATAGTGGTCTGCGGAACCGGTG
AGTA/TCACCGGAATC/TGCCG/AGGATGACCGG
GTCCTTTCTTGGAT/AT/CAACCCGCTCAATGCCC
G/CGAAATTTGGGCGTGCCCCCGCA/GAGACTGC
TAGCCGAGTAGTGTTGGG TCG CGA A/G GG.
Figure 2
The generated consensus sequence of the all patients
(5'UTR) used for generation of HCV specific siRNA.
Figure 1
Position entropy plots for sequences of all patients.
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times post-transfection using TRIZOL reagent (Life
T e c h n o l o g i e s ,G r a n dI s l a n d ,N Y ) .H u m a nG A P D H
siRNA was used as a control for HCV-siRNA.
Western blot analysis of HCV core antigens
in Huh-7 cells with and without siRNA
Uninfected Huh-7 cell and infected Huh-7 cells with and
without siRNA cell lysates were subjected to SDS-PAGE
as previously described [32]. After three washes, mem-
branes were incubated with diluted peroxidase-labeled
anti-human IgG/IgM antibody mixture at 1:5000 in PBS-
3 g/L for previously treated strips with the anti-core
(Novocastra, Novocastra Laboratories, UK) for 2 hr at
room temperature. Visualization of immune complexes
on the nitrocellulose membranes was done by develop-
ing the strips with 0.01 mol/L PBS (pH 7.4) containing
40 mg 3,3',5,5 tetramethylebenzedine and 100 μlo f3 0
ml/L hydrogen peroxide (Immunopure TMB substrate
Kit, PIERCE, Rockford, IIIinois, USA)
PCR of genomic RNA strands of HCV
Primers and probe
The primer used for reverse transcription (RT) of HCV
RNA was HCV-6: 5'-ACC.TCC-3' (nucleotides [nt] 319 to
324 [29]. The antisense PCR primer for HCV was RB-6B
(5'-ACT.CGC.AAG.CAC.CCT.ATC.AGG-3' [nt 292 to
312]) and the sense primer was RB-6A (5'-TG.AGG.
AAC.TAC.TGT.CTT.CAC.G-3' [nt 47 to 68]). The oligo-
nucleotide RB-6P (5'-TTG.GGT.CGC.GAA.AGG.CCT.
TGT.GGT.ACT.G-3' [nt 264 to 291]) was labeled at the
5' end with digoxigenin and was used as a probe in
hybridization experiments to determine the specificities
of the PCR products. The HCV oligonucleotides are
specific for the 5' un-translated region of the HCV
genome. The RT-PCR and the RNA template production
were performed as previously described [29, 30, 32-35].
Northern Blot Analysis
TotalRNA was extractedfrom allcell typesatDays1,2,3,4,
5, 6, 7 and 8 post transfection, and 5 ug of total RNA were
loaded onto the gel. HCV probe was generated from a BglII
fragment(47–1,032bp)oftheHCVplasmidpMOZ-1-HCV
using the MAXIscript In vitro transcription kit (Ambion).
Probing for the GAPDH transcript was performed as
described. Both probes were purified using the MicroSpin
G-50 columns (Amersham Pharmacia). Blots were visua-
lized and quantified as previously described [35]
Detection of plus and minus-strand RNA
by nested RT-PCR
Detection of plus- and minus- HCV strand was done
according to el-Awady et al. [32, 33]. The Step One real-
time PCR system (Applied Biosystems) was used.
Quantification of human GAPDH mRNA
We checked the integrity of the cellular RNA prepara-
tions from HCV infected Huh-7 cells, by quantification
of GAPDH mRNA in the absence and presence of siRNA
Z3 and siRNA Z5 respectively to ensure that the siRNA
used in this study did not adversely affect the expression
of a house keeping gene from host cells. GAPDH mRNA
levels were quantified by real time RT-PCR using
TaqMan technology with GAPDH specific primers [33].
Amplification of human GAPDH transcripts was per-
formed using the TaqMan EZ RT-PCR kit (Applied
Biosystems, Foster City, CA). The target template was
the purified cellular RNA from Huh-7 cells at 1, 2, 3, 4, 5,
6, 7 and 8 days post infection with HCV, in absence and
presence of our siRNA. Reverse transcription-PCR was
done using a single-tube, single-enzyme system. The
reaction exploits the 5'-nuclease activity of the rTth DNA
polymerase to cleave a TaqMan fluorogenic probe that
anneals to the cDNA during PCR between the forward
primer at nucleotide position 1457 and reverse primer at
nucleotide position 3412 of the human GAPDH gene. In
a5 0μl reaction volume, 1.5 μl of RNA template solution
equivalent to total cellular RNA from 2.5 × 10
5 cells were
mixed with 200 nM forward primer, 100 nM reverse
primer, 100 nM GAPDH probe, 300 μMf r o me a c ho f
dATP, dCTP, dGTP and 600 uM dUTP, 3 mM manganese
acetate, 0.5 u rTth DNA polymerase, 0.5 u Amp Erase
UNG, 1× Taqman EZ buffer and amplified in the
sequence detection system ABI 7700 (Applied Biosys-
tems, Foster City, CA). The RT-PCR thermal protocol was
as follows: Initial UNG treatment at 50°C for 2 minutes,
RT at 60°C for 30 minutes, deactivation of UNG at 95°C
for 5 minutes followed by 40 cycles, each of which
consists of denaturation at 94°C for 20 seconds and
annealing/extension at 62°C for 1 min.
Reverse Transcription and Real-Time PCR Analysis
for HCV
Total RNA was harvested with Trizol and purified as
recommended by the manufacturer (Invitrogen). One
microgram of total RNA was incubated with DNase 1 by
using the DNA-free kit (Ambion). cDNA was generated
by using the TaqMan reverse transcription reagents kit
(Applied Biosystems) according to manufacturer recom-
mendations. Reactions with no reverse transcriptase
enzyme added were performed in parallel with most
experiments and yielded no PCR products. Real-time
PCR (Applied Biosystems) was performed. To quantify
HCV transcript levels, dilutions of the in-vitro tran-
scribed HCV-plasmid PMOZ-1-HCV plasmids [35] con-
taining the HCV 5-UTR and core or the human GAPDH
gene were always run in parallel with cDNA from the
Huh-7 for use as standard curves (dilutions ranged from
10
8 to 100 copies of each plasmid). The PCR primers for
Virology Journal 2009, 6:13 http://www.virologyj.com/content/6/1/13
Page 4 of 9
(page number not for citation purposes)GAPDH are based on the human GAPDH mRNA
sequence (GenBank accession no. NMX002046), and
spans introns two and three of the GAPDH gene (base
pairs 1,457–3,412). The PCR primers for quantitative
real-time PCR were HCV RB6A 5'-TGAGGAAC-
TACTGTCTTCACG-3' (sense) and RB6B 5'-ACTCG-
CAAGCACCCTATCAGG-3' (antisense) [29] and
GAPDH 5'-GAAGGTGAAGGTCGGAGTC-3' (sense) and
5-GAAGATGGTGATGGGATTTC-3' (antisense).
Statistical analysis
The data shown in Figures 5 and 6 were carried out at
least in triplicates for each treatment and data averages
with standard errors of the means are shown.
Results
Since HCV replication in cell culture is limited to Huh-7
cells and their derivatives, we first verified that HCV can
replicate in the Huh-7 cells through detection of the viral
proteins Core by western blotting as well as detection of
viral copies by both real time PCR and b-DNA in both
cells and supernatant starting from Day 7 post transfec-
tion Figure 3 shows the expression level of the viral core
and GAPDH in Huh-7 cells infected by HCV genotype-4
from day 1 to day 7 (Table 1 and Figure 3).
Next, we assessed whether HCV antigen expression could
be silenced by using HCV-specific siRNAs. Two different
siRNA (Z3 and Z5) which target both 5-UTR and core
region were designed according to genotype 4 consensus
sequence (see material and methods). The integrity of
this region is associated with optimal translation of the
HCV polypeptide, and its sequence is maintained in all
HCV sequences in the gene data base. Huh-7 cells
containing HCV were transfected with 100 nM of the
siRNA and plated for eight days.
Protein lysates were made and immunoblots were
performed with mAbs specific for the HCV core. Viral
proteins levels were decreased after 24 hr of the
transfection of 100 nM of siRNA specific for HCV, and
this decrease continued for seven days with both Z5 and
Z3 siRNA (Figure 4A&B). Maximal inhibition of HCV
transcript levels was detected on Day 3 post transfection
with Z5 and Z3 siRNA and continued for three days by
Z3 and six days by Z5 (5.2- and 8.0-fold for Z3 and Z5;
respectively). No significant inhibition of HCV transcript
levels was detected in cells transfected with the negative
control siRNA (P = 0.4927; Table 1).
Total RNAs were harvested from both non-transfected
and transfected cells as well as from tissue culture
supernatant of both cultures at 1, 2, 3, 4, 5, 6,7 and 8
days after transfection. Quantitative analysis by real time
PCR revealed that HCV RNA levels decreased 18-folds
(P = 0.001) and 25-folds (P = 0.0005) in cells transfected
with Z3 and Z5; respectively, on Day 2 post transfection
and continued for Day 3 by Z3 and Day 7 by Z5 (Fig. 5, 6
&T a b l e1 ) .
Discussion
In many cases, it is difficult to eradicate HCV infection
even with an intensive antiviral therapy that utilizes
Table 1: The reduction rate of HCV-Core protein expression and HCV-RNA level in Huh-7 cells supporting HCV replication inhibited
by siRNA
Days **RNA titer
(untransfected) IU/ml
**RNA titer (Z3 used)
IU/ml
**RNA titer (Z5 used)
IU/ml
*C o r ep r o t e i n
reduction rate (Z5
used)
*C o r ep r o t e i n
reduction rate (Z3
used)
14 × 1 0
6 4×1 0
6 3.6 × 10
5 10% 0%
23 . 9 × 1 0
6 3×1 0
6 2.4 × 10
5 60% 75%
34 . 1 × 1 0
6 > 1000 > 1000 90% 100%
44 . 2 × 1 0
6 > 1000 > 1000 100% 100%
54 . 5 × 1 0
6 2.2 × 10
6 > 1000 100% 50%
63 . 8 × 1 0
6 2.89 × 10
6 > 1000 100% 30%
73 . 7 × 1 0
6 3.1 × 10
6 1.6 × 10
6 40% 30%
84 . 4 × 1 0
6 4×1 0
6 4.2 × 10
6 0% 0%
* Core protein expression by Western Blot
** RNA titer by Real Time PCR
Figure 3
The expression level of the viral core and GAPDH in
Huh-7 cells infected by HCV genotype-4 from day 1
to day 8.
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number of other antiviral compounds, including inhibi-
tors against the NS3-4A protease[36] and NS5B RNA
dependent RNA polymerase [37] are currently being
tested for their therapeutic applicability; such attempts
have not always been promising.
The HCV genome is a positive-sense single-stranded RNA
that functions as both a messenger RNA and replication
template via a negative-strand intermediate, making it an
attractive target for the study of RNA interference. Some
studies have demonstrated that siRNAs interfere with
HCV gene expression and replication [8, 28] others have
reported the use of siRNA against HIV-1, HPV and
poliovirus in culture cells [27]. In the current study, we
were able to show that the introduction of siRNA-5-UTR
into target cells that contain e dH C V ,c a u s e dad r a m a t i c
decrease of viral RNA and protein levels (Figures 4 and 5).
This effect was likely due to the degradation of HCV
messenger RNA by the RISC endonuclease. We noticed that
the effect of RNAi on HCV replication occurs very early
after 24 hours post siRNA transfection. Our data is in
agreement with McCaffrey et al., [8] who showed that, a
fragment of the HCV NS5B RNA polymerase gene, which
was transiently co-transfected with siRNA into mouse liver
by hydrodynamic injection, was cleaved after treatment
with siRNA. Our data are also consistent with those of
Randall and associates [38] who demonstrated that siRNA
targets and cleaves the HCV 5'UTR efficiently and
specifically. More importantly, they showed that the
cleavage of HCV-RNA not only suppressed viral protein
synthesis, but also blocked the replication of sub-genomic
viral RNA.
A
B
Figure 4
A. The expression level of the viral core in Huh-7
cells infected by HCV genotype-4 from day 1 to day 8.
Upper row showed HCV-core expression in un-transfected
cells. Lower row showed the HCV- core expression in
siRNA-Z5 transfected cells. 4B The expression level of the
viral core in Huh-7 cells infected by HCV genotype-4 from
day 1 to day 8. Upper row showed HCV-core expression in
un-transfected cells. Lower row showed the HCV- core
expression in siRNA-Z3 transfected cells.
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Figure 5
The reduction in HCV- core protein after
transfection with Z5 and Z3 siRNA in Huh-7 cells
harboring HCV-genotype-4.
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The reduction in HCV copies/ml after transfection
with Z5 and Z3 siRNA in Huh-7 cells harboring HCV-
genotype-4.
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such as HCV, are notoriously prone to errors during their
replication, and continuously produce mutated viral
proteins to escape immune-system defense mechanisms
[39]. These mutations may also escape attack by siRNAs.
The protein-coding sequence of the HCV genome that
was targeted in the study by McCaffrey et al., [8] varies
considerably among different HCV genotypes, and even
among strains of the same genotype [40]. In addition,
given the high error rate of the non-proofreading HCV
RNA-dependent RNA polymerase, the so-called 'siRNA
escape mutants' which have silent mutations in the
protein-coding sequence, could emerge quickly. In
contrast, the 5'UTR, which was selected as a target in
the present study, is almost identical among the known
strains of HCV. Moreover, structural constraints on the
5'UTR, in terms of its ability to direct internal ribosome
entry and translation of viral proteins, would not permit
escape mutations.
Therefore, the 5'UTR of the HCV genome appears to be
an ideal target for siRNA in clinical applications. Not all
5'-UTR-directed siRNAs were equally effective; among
the siRNAs tested by Yokota et al. [41], siRNA 331, which
is directed against a region upstream of the start codon,
was the most efficient, whereas siRNA 82, which is
directed against helix II, had almost no effect on viral
genome expression. These results may be due to the
highly folded structure of the 5'UTR, which may leave
few single-stranded gaps that siRNAs can access. Addi-
tionally, it has been reported that the target region of
siRNA 331 is also an efficient target site for a catalytic
RNA, a hammerhead ribozyme, for the suppression of
HCV protein expression [42]. Yokota et al., [41]
demonstrated that the secondary structure of the HCV
RNA genome influences the efficiency of siRNAs at least
in part. They also showed that the siRNAs suppressed the
expression of an HCV replicon more potently than did
the IRES reporter vector. This stronger suppressive effect
of siRNA on the HCV replicon might be due to several
effects on its autonomous replication mechanism. The
blockage of the IRES-mediated synthesis of the non-
structural proteins, which is essential for viral RNA
synthesis, and the cleavage of elements in the 5'UTR that
are necessary to prime complementary RNA strand
synthesis, may result in further suppression of viral
replication. They were also able to show that siRNAs not
only reduced viral protein synthesis, but also abolished
intracellular replication of the viral genomic RNA,
raising the possibility that RNAi could achieve the
elimination of viruses from persistently infected host
cells. Cleavage of the HCV IRES by siRNAs may lead to
complicated effects on protein translation. It has been
reported that the most 5'part of the UTR may negatively
regulate the IRES function [43]. Moreover, deletion of
the nucleotides that make up helix 1 leads to an increase
in IRES-mediated translation [44]. Yokota et al., [41]
suggested that the cleavage of helix I by siRNA 12 led to
an enhancement of IRES mediated translation through
the inactivation of cis- or trans-acting negative regulatory
elements of the IRES.
Our results demonstrate for the first time that careful
selection of target sequences for siRNAs is mandatory,
not only to achieve maximum efficiency (as with siRNA
Z5), but also to avoid adverse effects in therapeutic
applications. We elected to make use of Huh-7 cells
infected with native viral particles from HCV type-4
positive serum, the most prevalent type in Egypt. We
were able to maintain these cells in culture for more than
six months. The cells were also capable of supporting
HCV replication as indicated by consistent synthesis of
plus and minus RNA strands by nested RT-PCR and by
real-time PCR technique.
As efficient and safe delivery methods of siRNAs to cells
in vivo that can suppress HCV replication in all infected
cells have not been established yet, chemically modified
synthetic siRNA might easily be made and delivered into
cells on their own. Recently, it was reported that serum
(ribonuclease)-resistant modified siRNA can be deliv-
ered into cells without a cationic lipid carrier [45]. On
the other hand, the great variability in RNA sequences
between different quasispecies and genotypes of HCV
makes the use of one siRNA less effective in the
therapeutic applications. Therefore, several different
combinations of siRNA are necessary to target a
particular region of the genome.
To assess this hypothesis we used consensus siRNA
which considered four siRNAs at the same time and
showed a great inhibitory effect. We showed that the two
siRNAs we selected, Z3-siRNA (nt 41–57; from the 5'UTR
and nt 173–189 from the core area) and Z5-siRNA- (nt
59–79 from the 5'UTR and nt 109–129 from the core
area), completely inhibited viral replication in culture,
thus confirming earlier reports on siRNA and suggesting
a potential therapeutic value in HCV type-4. Our
preliminary data indicate that siRNA Z5 efficiently
suppresses HCV replication in vitro.
We conclude that the utility of siRNA as a therapy against
HCV infection will depend on the development of
efficient delivery systems that induces long-lasting RNAi
activity. HCV is an attractive target because of its
localization in the infected liver, an organ that can be
readily targeted by nucleic acid molecules and viral
vectors. Also, gene therapy offers another possibility to
express siRNAs that target HCV in a patient's liver. The
data in this study suggest that siRNAs targeting 5'UTR
Virology Journal 2009, 6:13 http://www.virologyj.com/content/6/1/13
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culture. It represents a promising therapy that could
eliminate viral RNA from the infected cell and poten-
tially cure patients with HCV. In conclusion, the
efficiency of our siRNAs in inhibiting HCV replication
in cells suggests that this RNA-targeting approach might
provide an effective therapeutic option for HCV infec-
tion, especially at the optimal site within the conserved
5'UTR. Also, double hit Z5 siRNA is more effective in the
inhibition of viral replication at the same concentration
of Z3 siRNA.
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